Hypothesis

A precision synbiotic regimen—combining a specific resistant starch (RS2) prebiotic with the GABA‑producing probiotic Lactiplantibacillus plantarum Lp815—will produce a clinically significant reduction in depressive symptoms only in individuals whose baseline fecal microbiome shows a low Faecalibacterium prausnitzii abundance coupled with a high Proteobacteria/Bacteroidetes ratio. In this subgroup, RS2 selectively fuels butyrate‑producing taxa, raising luminal butyrate that upregulates GABA transporter expression in colonic enteroendocrine cells, thereby amplifying probiotic‑derived GABA release. The increased GABA activates vagal afferents, dampening amygdala hyperactivity and normalizing prefrontal‑limbic connectivity, leading to antidepressant efficacy comparable to standard SSRIs.

Mechanistic Rationale Beyond Cited Work

• Butyrate as a GABA modulator: While SCFAs are known to influence neuroinflammation, recent epigenomic data show that butyrate inhibits histone deacetylase 3 (HDAC3) in colonic enteroendocrine cells, increasing transcription of the GABA transporter GAT‑1 (SLC6A1). Elevated GAT‑1 enhances GABA uptake into these cells, followed by calcium‑dependent vesicular release into the lumen. This mechanism links prebiotic‑driven butyrate to amplified probiotic GABA output, a step not addressed in the existing literature.
• Microbiome‑stratified vulnerability: Low F. prausnitzii reflects diminished butyrate synthesis capacity, while a high Proteobacteria/Bacteroidetes ratio indicates a proinflammatory milieu that compromises gut barrier function and vagal tone. Individuals with this signature are predicted to have the greatest “butyrate deficit” and thus the most to gain from RS2‑induced butyrate augmentation.
• Counteracting psychotropic‑induced dysbiosis: SSRIs and SNRIs have been shown to reduce overall microbial diversity and butyrate producers. By restoring butyrate levels, the synbiotic may mitigate medication‑induced microbiome shifts that otherwise blunt therapeutic response, creating a permissive environment for both the probiotic GABA effect and the psychotropic drug.

Testable Predictions

1. Primary outcome: In a 12‑week, double‑blind, placebo‑controlled RCT, participants receiving the RS2 + Lp815 synbiotic will show a greater reduction in MADRS scores than placebo only within the predefined microbiome‑stratified subgroup (low F. prausnitzii < 5 % relative abundance, Proteobacteria/Bacteroidetes > 1.5). No significant difference will be observed in the rest of the cohort.
2. Secondary outcomes: The responsive subgroup will exhibit (a) a ≥ 20 % increase in fecal butyrate concentration, (b) a ≥ 15 % rise in urinary GABA excretion, and (c) enhanced resting‑state functional connectivity between the ventromedial prefrontal cortex and amygdala (measured by fMRI) correlating with symptom improvement.
3. Mechanistic validation: In a subset, colonic biopsies (via flexible sigmoidoscopy) will show upregulated GAT‑1 mRNA expression in enteroendocrine cells after synbiotic treatment, which will be absent in non‑responders.

Experimental Design

• Population: 300 adults diagnosed with moderate‑to‑severe major depressive disorder (MDD), not currently on antidepressants or willing to wash out for 2 weeks.
• Stratification: Baseline shotgun metagenomics to quantify F. prausnitzii, Proteobacteria, and Bacteroidetes. Participants divided into “signature‑positive” (criteria above) and “signature‑negative” groups.
• Intervention: Daily RS2 (30 g) plus Lp815 Lp815 (1 × 10¹⁰ CFU) versus matched placebo (maltodextrin).
• Assessments: MADRS at baseline, weeks 4, 8, 12; fecal SCFAs (GC‑MS); urinary GABA (LC‑MS/MS); fMRI at baseline and week 12; optional biopsies at week 12.
• Analysis: Mixed‑effects model with interaction term (treatment × signature) for primary outcome; mediation analysis testing whether changes in butyrate and GABA mediate symptom change.

Potential Confounds and Mitigations

• Dietary fiber intake: Participants will keep a standardized low‑FODMAP background diet to reduce variability in endogenous fermentable substrates.
• Psychotropic use: Washout period and prohibition of concomitant antidepressants; rescue medication allowed only after week 8 with subsequent censoring.
• Placebo effect of probiotic: Use of an inert probiotic strain (e.g., Lactococcus lactis) in placebo arm to control for nonspecific microbial exposure.

Falsifiability

The hypothesis is falsifiable if, after the trial, the synbiotic fails to produce a significantly greater MADRS reduction than placebo in the signature‑positive group, or if the biomarker changes (butyrate, urinary GABA, GAT‑1 expression) do not correlate with clinical improvement. Conversely, a positive result limited to the signature‑positive stratum, accompanied by the predicted mechanistic shifts, would support the hypothesis and justify further development of microbiome‑guided synbiotic adjuncts for depression.

1 2 3 4 5 6 7